List of Excipients in Branded Drug BROMSITE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Sun Pharmaceutical Industries Inc	BROMSITE	bromfenac	49708-754	ANHYDROUS CITRIC ACID
Sun Pharmaceutical Industries Inc	BROMSITE	bromfenac	49708-754	BENZALKONIUM CHLORIDE
Sun Pharmaceutical Industries Inc	BROMSITE	bromfenac	49708-754	BORIC ACID
Sun Pharmaceutical Industries Inc	BROMSITE	bromfenac	49708-754	EDETATE DISODIUM

BromSite Excipient Strategy and Commercial Opportunities in Ophthalmic Drug Delivery

Last updated: September 5, 2026

BromSite is a bromfenac ophthalmic solution containing bromfenac sodium, marketed by Sun Pharmaceutical Industries for postoperative ocular inflammation and prevention of ocular pain after cataract surgery. Its commercial differentiation comes less from the active ingredient than from the formulation platform: a topical ocular solution using DuraSite bioadhesive technology to increase ocular residence time and support once-daily dosing. The main excipient opportunities are preservative-free reformulation, polymer optimization, container-closure improvements, and differentiated generic or authorized-generic products.

What is BromSite and how does its formulation work?

BromSite is a sterile ophthalmic solution containing bromfenac sodium equivalent to 0.075% bromfenac. The U.S. Food and Drug Administration approved BromSite in 2016 under NDA 205311 for treatment of postoperative inflammation and prevention of ocular pain in patients undergoing cataract surgery.[1]

Attribute	BromSite profile
Active ingredient	Bromfenac sodium
Strength	0.075% bromfenac
Dosage form	Sterile topical ophthalmic solution
Indication	Postoperative inflammation and prevention of ocular pain after cataract surgery
Dosing	One drop in the affected eye once daily, beginning one day before surgery and continuing for 14 days after surgery
Sponsor	Sun Pharmaceutical Industries, Inc.
FDA approval	2016
Formulation platform	DuraSite ocular bioadhesive technology
Preservative	Benzalkonium chloride
Primary commercial differentiator	Once-daily dosing with enhanced ocular residence

BromSite uses DuraSite, a bioadhesive formulation platform associated with increased retention on the ocular surface. The formulation is designed to reduce rapid drainage through blinking and the nasolacrimal system. Longer residence can improve exposure at the cornea and anterior segment while reducing administration frequency.

The product’s formulation is important because bromfenac ophthalmic products compete in a class where active pharmaceutical ingredient differentiation is limited. Products containing bromfenac, ketorolac, nepafenac, or diclofenac compete through dosing frequency, onset, tolerability, postoperative outcomes, packaging, and surgeon preference.

What excipients are used in BromSite?

The BromSite label identifies a conventional ophthalmic excipient system built around buffering, tonicity adjustment, chelation, preservation, and bioadhesive retention.[2]

Excipient function	BromSite excipient strategy
Bioadhesion and ocular residence	DuraSite polymer platform
Buffering	Boric acid and sodium borate
Tonicity adjustment	Sodium chloride
Chelation	Edetate disodium
Preservation	Benzalkonium chloride
Vehicle	Sterile purified water

The formulation has a pH and osmolality range intended to support ocular tolerability and product stability. Edetate disodium can improve preservative performance by binding divalent metal ions that support microbial growth or destabilize the formulation. Borate buffering helps maintain pH during storage and use.

The most commercially significant excipient is the DuraSite polymer system. A conventional bromfenac solution may drain rapidly from the eye and require more frequent administration. A bioadhesive vehicle can support longer contact with the ocular surface, which is directly linked to the once-daily commercial positioning of BromSite.

How does DuraSite create commercial value?

DuraSite is the central formulation asset in BromSite. The technology is designed to increase topical ocular retention without converting the product into a gel or suspension that would materially impair administration.

The commercial value has four components:

1. Reduced dosing frequency compared with older topical NSAID regimens.
2. Greater opportunity for sustained exposure at the ocular surface.
3. A formulation-based differentiation strategy despite a well-established active ingredient.
4. Potential regulatory complexity for generic applicants seeking to demonstrate pharmaceutical equivalence and therapeutic equivalence.

The formulation must balance competing properties. Higher polymer concentration may increase residence time but can also increase viscosity, blur vision, affect drop size, complicate manufacturing, and worsen patient acceptance. Lower polymer concentration may improve drop comfort but weaken the product’s retention advantage.

For a follow-on product, matching bromfenac concentration alone may not reproduce BromSite’s clinical performance. The applicant may need to address polymer identity, polymer molecular weight, rheology, pH, osmolality, drop size, preservative concentration, container compatibility, and in-use stability.

What excipient strategies could improve BromSite?

Preservative-free BromSite

BromSite contains benzalkonium chloride, a widely used ophthalmic preservative. Repeated exposure to benzalkonium chloride can contribute to ocular-surface irritation, epithelial toxicity, and tear-film disruption, particularly in patients with pre-existing dry eye or prolonged postoperative treatment.[3]

A preservative-free version could target:

• Patients with ocular-surface disease.
• Cataract surgeons focused on postoperative comfort.
• Patients using multiple preserved ophthalmic products.
• Premium ophthalmic markets.
• Hospital and ambulatory surgery channels seeking lower preservative exposure.

A preservative-free product would require a different packaging strategy. Likely options include unit-dose containers, multidose preservative-free valves, or a container system with validated microbial protection. Each option creates cost, filling, extractables, leachables, and usability considerations.

A preservative-free multidose product would have the strongest commercial appeal because it could preserve convenience and reduce packaging waste. It would also present the greatest technical burden. The container must prevent microbial ingress without relying on benzalkonium chloride or another preservative.

Polymer optimization

A second opportunity is optimization of the bioadhesive polymer system. Relevant variables include:

• Polymer concentration.
• Polymer molecular weight and crosslink density.
• Viscosity at shear rates associated with blinking.
• Mucoadhesion under tear-fluid dilution.
• Compatibility with bromfenac sodium.
• Effect on drop size and dose uniformity.
• Optical clarity after storage.
• Interaction with the bottle and dispensing tip.

A formulation that improves retention without creating transient visual blur could support premium positioning. The same platform could be applied to other ophthalmic anti-inflammatory drugs, antibiotics, corticosteroids, and combination products.

Reduced-irritation preservation

If a fully preservative-free formulation is not commercially viable, a reformulation could seek lower benzalkonium chloride exposure or use an alternative preservative system. The opportunity is limited by ophthalmic regulatory requirements and by the need to demonstrate antimicrobial effectiveness, stability, and ocular tolerability.

A lower-preservative product may provide a more practical intermediate strategy than full preservative elimination. It could support lifecycle management while reducing development and packaging complexity.

Container-closure engineering

The bottle is part of the product’s formulation performance. Important design parameters include:

• Drop-volume consistency.
• Residual volume.
• Protection from light and oxygen.
• Compatibility with the polymer vehicle.
• Low sorption of bromfenac or excipients.
• Low extractables and leachables.
• Usability for elderly postoperative patients.

A redesigned bottle could create a differentiated product without changing the active ingredient. A smaller nominal drop size could reduce systemic exposure and medication waste, although the product would need to preserve adequate ocular delivery and dosing reliability.

What commercial opportunities exist for generic and follow-on BromSite products?

Generic entry is technically more difficult than entry for a conventional small-molecule ophthalmic solution when the reference product uses a proprietary bioadhesive vehicle. The active ingredient is established, but the formulation may involve product-specific performance characteristics.

Potential follow-on strategies include:

Strategy	Commercial benefit	Main development barrier
Conventional bromfenac solution	Lower manufacturing cost	May not reproduce DuraSite residence
Bioadhesive generic	Closer reference-product positioning	Polymer equivalence and performance testing
Preservative-free version	Premium ocular-surface positioning	Packaging and microbial protection
Lower-strength product	Potential tolerability or dosing differentiation	Clinical and regulatory justification
Fixed combination	Reduced postoperative drop burden	Compatibility and clinical development
Authorized generic	Faster market access	Dependence on originator agreement
Regional licensing	Local market access	Regulatory and supply-chain coordination

A conventional generic could compete on price while giving up some of BromSite’s formulation differentiation. A bioadhesive generic would likely have greater commercial value but face a more demanding development program.

The generic opportunity also depends on the regulatory pathway. FDA requirements for ophthalmic products can include comparative physicochemical characterization, sterility, preservative effectiveness, stability, and, depending on the product and formulation differences, additional clinical or in vivo studies. The relevant standard is not simply sameness of bromfenac concentration.

What is the FDA and Orange Book status of BromSite?

BromSite was approved by FDA under NDA 205311 in 2016. The product is an FDA-approved prescription ophthalmic drug and is listed in FDA drug databases under bromfenac sodium ophthalmic solution.[1,2]

The Orange Book is the controlling source for current patent and exclusivity listings, including any listed patents, pediatric exclusivity, and therapeutic-equivalence designations. Public product labeling confirms FDA approval but does not, by itself, establish the current scope or expiration of every listed patent claim.

For commercial diligence, the relevant regulatory questions are:

• Whether BromSite has active Orange Book-listed patents.
• Whether any listed claims cover the DuraSite vehicle.
• Whether claims cover the method of postoperative ocular treatment.
• Whether a generic applicant could file an ANDA with Paragraph IV certification.
• Whether any litigation has been filed after a Paragraph IV notice.
• Whether settlement terms restrict launch timing.
• Whether the product has an authorized generic or license arrangement.

No reliable conclusion on current patent expiration dates or Paragraph IV litigation should be drawn without reviewing the current FDA Orange Book record and federal court docket.

What patent claims are most important for BromSite?

The highest-value intellectual property would generally fall into four categories.

Formulation patents

These may claim combinations of bromfenac sodium with a bioadhesive polymer, buffer, tonicity agent, preservative, or specific pH and viscosity ranges. Formulation claims are commercially important because they can remain relevant even after basic active-ingredient protection expires.

Method-of-use patents

Method claims may cover once-daily administration, preoperative dosing, postoperative treatment, or prevention of ocular pain and inflammation after cataract surgery. Their enforceability depends on claim language, labeling, induced-infringement evidence, and the availability of non-infringing generic labeling.

Platform patents

DuraSite-related patents may protect the polymer vehicle or its use across multiple ophthalmic products. Platform patents can have licensing value beyond BromSite if the same technology is used in other drug products.

Manufacturing and packaging patents

Claims may address sterile manufacture, polymer hydration, mixing order, filtration, bottle filling, dropper design, or container systems. These patents can create practical barriers even when they do not fully block a competing product.

How strong is the BromSite formulation strategy?

BromSite has a commercially credible formulation strategy because its value is linked to dosing convenience rather than only to bromfenac’s pharmacology. The principal strengths are once-daily dosing, a recognized ocular bioadhesive platform, and a product profile aligned with postoperative cataract care.

The principal weaknesses are benzalkonium chloride exposure, reliance on a specialized vehicle, and the possibility that generic manufacturers can compete with simpler bromfenac formulations at lower prices. The formulation also faces pressure from alternative NSAIDs and corticosteroid products that may be prescribed in combination after cataract surgery.

Patent strength depends on the breadth and remaining term of the relevant claims. A narrow claim limited to a specific polymer concentration or excipient ratio may be vulnerable to design-around. Broader claims covering the platform, formulation architecture, and method of use would provide stronger commercial protection.

How does BromSite compare with competing ophthalmic NSAIDs?

Product	Active ingredient	Typical differentiation	Excipient opportunity
BromSite	Bromfenac 0.075%	Once-daily dosing and DuraSite retention	Preservative-free bioadhesive reformulation
Prolensa	Bromfenac 0.07%	Once-daily bromfenac formulation	Drop-size and ocular-surface improvements
Nevanac	Nepafenac	Prodrug conversion to amfenac	Suspension stability and comfort
Acular/ketorolac products	Ketorolac	Established low-cost NSAID class	Preservative reduction and multidose packaging
Diclofenac ophthalmic products	Diclofenac	Earlier-generation NSAID option	Stability and tolerability improvements

BromSite competes most directly with Prolensa because both are once-daily bromfenac products. BromSite’s DuraSite platform gives it a formulation-based differentiation, while Prolensa competes through its own bromfenac formulation and established brand presence.

What licensing opportunities exist around BromSite excipients?

The most attractive licensing opportunities are likely to involve technology rather than bulk excipient supply.

Potential counterparties include:

• Ophthalmic polymer developers.
• Preservative-free multidose packaging companies.
• Specialty generics manufacturers.
• Contract development and manufacturing organizations.
• Regional pharmaceutical companies.
• Companies with cataract-surgery portfolios.
• Suppliers of ophthalmic-grade polymers and container systems.

A platform license could support use of a DuraSite-type vehicle in additional ophthalmic products. A packaging license could enable a preservative-free BromSite lifecycle product. A regional license could combine Sun Pharma’s product rights with a local partner’s manufacturing, registration, or distribution infrastructure.

Bulk excipient supply is less defensible unless the supplier controls a pharmaceutical-grade polymer with validated performance, regulatory documentation, and a reliable global supply chain. The strongest negotiating position lies with suppliers whose material is difficult to substitute without reformulation and new regulatory work.

What generic launch risks exist for BromSite?

Generic launch risk is driven by four factors:

1. Orange Book patent status and remaining patent term.
2. The ability to replicate or design around the DuraSite vehicle.
3. FDA requirements for demonstrating equivalence of a complex ophthalmic solution.
4. Physician willingness to substitute a lower-cost formulation.

A first generic entrant could pressure BromSite pricing even if it does not fully replicate the branded bioadhesive system. A formulation-matched generic would create greater erosion risk because it could compete directly on dosing and product performance.

The most defensible commercial position is a product with a documented retention advantage, a better ocular-surface profile, or a meaningful packaging benefit. Price alone is less durable once multiple ophthalmic NSAID products are available.

Key Takeaways

• BromSite is a once-daily bromfenac ophthalmic solution approved for postoperative cataract-surgery inflammation and pain prevention.
• Its main formulation differentiator is DuraSite bioadhesive technology, not the bromfenac active ingredient.
• The most attractive excipient opportunities are preservative-free delivery, polymer optimization, and advanced multidose packaging.
• Benzalkonium chloride creates a clear lifecycle-management opportunity for patients with ocular-surface sensitivity.
• Generic development may be more complex than for a conventional bromfenac solution because the vehicle contributes to product performance.
• The most valuable IP would cover the bioadhesive formulation, platform technology, method of use, and container-closure system.
• Current patent expiration, Orange Book listings, Paragraph IV challenges, and settlement status require verification against the current FDA and court records.
• BromSite’s strongest competitive risk comes from Prolensa and lower-cost bromfenac or ketorolac products.

FAQs

Can BromSite be reformulated without benzalkonium chloride?

Yes. A preservative-free formulation could use unit-dose packaging or a validated preservative-free multidose container. The principal challenges are microbial protection, stability, usability, and regulatory comparability.

Is DuraSite an active pharmaceutical ingredient?

No. DuraSite is a formulation technology intended to improve ocular retention. It does not provide the anti-inflammatory activity of bromfenac sodium.

Would a generic BromSite need to use DuraSite?

Not necessarily. A generic applicant could pursue a different formulation, but it would need to satisfy FDA requirements for pharmaceutical equivalence and therapeutic equivalence. A different vehicle could affect residence time, dosing, tolerability, and clinical performance.

What is the strongest lifecycle-management product for BromSite?

A preservative-free, once-daily BromSite formulation in a reliable multidose container would likely offer the clearest lifecycle-management position. A fixed combination with another postoperative ophthalmic agent could offer a second pathway but would require broader clinical and regulatory development.

Which excipient has the greatest commercial value in BromSite?

The bioadhesive polymer system has the greatest value because it supports the product’s once-daily dosing and formulation differentiation. Benzalkonium chloride is commercially important as a preservation component but also creates the clearest opportunity for reformulation.

References

1. U.S. Food and Drug Administration. (2016). BromSite (bromfenac ophthalmic solution) 0.075%: Approval letter and prescribing information. FDA.

2. DailyMed. (n.d.). BromSite: Bromfenac sodium ophthalmic solution, 0.075%. National Library of Medicine.

3. U.S. Food and Drug Administration. (2019). Ophthalmic drug products for over-the-counter human use: Guidance for industry. FDA.

4. U.S. Food and Drug Administration. (2023). Approved drug products with therapeutic equivalence evaluations, Orange Book. FDA.

5. American Academy of Ophthalmology. (2022). Corneal epithelial toxicity and preservatives in topical ophthalmic medications. American Academy of Ophthalmology.